Alissa Huston is a Rochester native who received her medical degree at the University of Buffalo, and went on to complete an Internal Medicine residency at Strong Memorial Hospital. She then attended the University of Pittsburgh for her Hematology/Oncology fellowship, during which time she was involved in research involving bone metastasis in cancer. Currently, she is an Associate Professor of Medicine at the Wilmot Cancer Institute at the University of Rochester, where her clinical efforts are focused on breast cancer. She is also the Co-Medical Director of the Pluta Integrative Oncology & Wellness Center. Her research efforts focus on understanding the effects of treatment for breast cancer upon bone health and how integrative modalities can help mitigate symptoms for cancer patients as they undergo treatment. She is a member of the American Society of Clinical Oncology and the Society for Integrative Oncology. Her philosophy is that there is no singular approach to patient care. Even though many patients may carry the same diagnosis, each individual is affected by that illness in a different way. Patients are not perceived as just a number, but instead approached and treated as the unique individuals they represent.

Faculty Appointments

Associate Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, University of Pittsburgh School of Medicine-GME. 2003 - 2006

Residency, Internal Medicine, University of Rochester Medical Center. 2001 - 2003

Internship, Internal Medicine, University of Rochester Medical Center. 2000 - 2001

Education

MD | SUNY at Buffalo-School of Medicine & Biomedical Sciences (USA). 2000

Awards

Jacob Gitelman Award. 2014

Lawrence A. Kohn Senior Teaching Fellowship Award. 2009 - 2011

ASH Clinical Research Training Institute (ASH-CRTI) Award. Phase I Trial of Perifosine and 17-DMAG in Patients with Relapsed/Ref. 2005

ASCO/AACR Workshop Methods in Clinical Cancer Research Award. A Phase II Study Evaluating the Effects of COX-2 Inhibition on Lev. 2005

Cancer Education Consortium Workshop Award: Clinical Pharmacology of Anticancer Agents. 2004

AMWA Janet M. Glasgow Memorial Achievement Citation. 2000

Induction into Alpha Omega Alpha Society. 1999

James A. Gibson Anatomical Society Award. 1997

Research

Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant therapy for Triple Receptor-Negative Breast Cancer or Positive Lymph Nodes After Neoadjuvant Chemotherapy

Lead Researcher: Alissa Huston

The purpose of this study is to compare treated subjects' invasive disease-free survival of patients with triple-negative breast cancer after neoadjuvant chemotherapy.

Publications

Journal Articles

Problem-solving skills training in adult cancer survivors: Bright IDEAS-AC pilot study.

Noyes K, Zapf AL, Depner RM, Flores T, Huston A, Rashid HH, McNeal D, Constine LS, Fleming FJ, Wilding GE, Sahler OJZ

Cancer treatment and research communications.. 2022 March 2531 :100552. Epub 03/25/2022.

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA,

The New England journal of medicine.. 2022 March 24386 (12):1143-1154. Epub 1900 01 01.

An Atypical Presentation of Hemophagocytic Lymphohistiocytosis (HLH) Secondary to Occult Hodgkin Lymphoma.

Komisarof J, McGann K, Huston A, Katerji H, Morgan MA

Case reports in hematology.. 2021 2021 :6672257. Epub 07/24/2021.

The IAP Antagonist SM-164 Eliminates Triple-Negative Breast Cancer Metastasis to Bone and Lung in Mice.

Lei W, Duan R, Li J, Liu X, Huston A, Boyce BF, Yao Z

Scientific reports.. 2020 April 2410 (1):7004. Epub 04/24/2020.

Information and Emotional Support Needs of Families Whose Infant Was Diagnosed With SCID Through Newborn Screening.

Raspa M, Lynch M, Squiers L, Gwaltney A, Porter K, Peay H, Huston A, Fitzek B, Boyle JG

Frontiers in immunology.. 2020 11 :885. Epub 05/06/2020.

The Landscape of Severe Combined Immunodeficiency Newborn Screening in the United States in 2020: A Review of Screening Methodologies and Targets, Communication Pathways, and Long-Term Follow-Up Practices.

Sheller R, Ojodu J, Griffin E, Edelman S, Yusuf C, Pigg T, Huston A, Fitzek B, Boyle JG, Singh S

Frontiers in immunology.. 2020 11 :577853. Epub 10/28/2020.

The effects of high-dose calcitriol and individualized exercise on bone metabolism in breast cancer survivors on hormonal therapy: a phase II feasibility trial.

Peppone LJ, Ling M, Huston AJ, Reid ME, Janelsins MC, Puzas JE, Kamen C, Del Giglio A, Asare M, Peoples AR, Mustian KM

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.. 2018 August 26 (8):2675-2683. Epub 02/22/2018.

Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy.

Williams AM, Shah R, Shayne M, Huston AJ, Krebs M, Murray N, Thompson BD, Doyle K, Korotkin J, van Wijngaarden E, Hyland S, Moynihan JA, Cory-Slechta DA, Janelsins MC

Journal of neuroimmunology.. 2018 January 15314 :17-23. Epub 10/18/2017.

Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.

Turner BM, Skinner KA, Tang P, Jackson MC, Soukiazian N, Shayne M, Huston A, Ling M, Hicks DG

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.. 2015 July 28 (7):921-31. Epub 05/01/2015.

Cost effectiveness analysis of genetic testing for breast and ovarian cancer susceptibility genes: BRCA1 and BRCA2.

Kaldate R, Huston A, McCoy H, Cardeiro D, Noyes K

The breast journal.. 2014 20 (3):325-6. Epub 04/08/2014.

Dedicated Breast CT: Feasibility for Monitoring Neoadjuvant Chemotherapy Treatment.

Vedantham S, O'Connell AM, Shi L, Karellas A, Huston AJ, Skinner KA

Journal of clinical imaging science.. 2014 4 :64. Epub 11/29/2014.

Axillary recurrence (AR) after negative sentinel node biopsy (SNB): Who is at risk?

Hicks DG, Tang P, Shayne M, Huston A, Ling MN, Skinner KA

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2012 September 2030 (27_suppl):180. Epub 1900 01 01.

Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease.

D'Souza S, del Prete D, Jin S, Sun Q, Huston AJ, Kostov FE, Sammut B, Hong CS, Anderson JL, Patrene KD, Yu S, Velu CS, Xiao G, Grimes HL, Roodman GD, Galson DL

Blood.. 2011 December 22118 (26):6871-80. Epub 10/31/2011.

Few changes observed in polysomnographic-assessed sleep before and after completion of chemotherapy.

Roscoe JA, Perlis ML, Pigeon WR, O'Neill KH, Heckler CE, Matteson-Rusby SE, Palesh OG, Shayne M, Huston A

Journal of psychosomatic research.. 2011 December 71 (6):423-8. Epub 09/22/2011.

The effect of various vitamin D supplementation regimens in breast cancer patients.

Peppone LJ, Huston AJ, Reid ME, Rosier RN, Zakharia Y, Trump DL, Mustian KM, Janelsins MC, Purnell JQ, Morrow GR

Breast cancer research and treatment.. 2011 May 127 (1):171-7. Epub 03/08/2011.

An exploratory study on the effects of an expectancy manipulation on chemotherapy-related nausea.

Roscoe JA, O'Neill M, Jean-Pierre P, Heckler CE, Kaptchuk TJ, Bushunow P, Shayne M, Huston A, Qazi R, Smith B

Journal of pain and symptom management.. 2010 September 40 (3):379-90. Epub 06/25/2010.

The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review.

Peppone LJ, Hebl S, Purnell JQ, Reid ME, Rosier RN, Mustian KM, Palesh OG, Huston AJ, Ling MN, Morrow GR

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.. 2010 July 21 (7):1133-49. Epub 12/04/2009.

Cost-effectiveness of testing for breast cancer susceptibility genes.

Holland ML, Huston A, Noyes K

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.. 2009 12 (2):207-16. Epub 07/18/2008.

Involvement of hepcidin in the anemia of multiple myeloma.

Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, Roodman GD, Ganz T, Lichtenstein A

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2008 June 114 (11):3262-7. Epub 1900 01 01.

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.

Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2008 February 114 (3):865-74. Epub 1900 01 01.

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.

Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2006 November 1512 (22):6826-35. Epub 1900 01 01.

Role of the microenvironment in multiple myeloma bone disease.

Huston A, Roodman GD

Future oncology.. 2006 June 2 (3):371-8. Epub 1900 01 01.

Books

Translational Therapeutic Strategies in Multiple Myeloma (2007)

Chapter: Myeloma Bone Disease

Authors: A. Huston and G. D. Roodman

Publisher: Informa Healthcare, Inc. 2007

Cancer Supportive Care: Advances in Therapeutic Strategies (2007)

Chapter: Skeletal Complications: Bone Metabolism and Novel Targeted Agents

Authors: A. Huston

Publisher: Informa healthcare, Inc. 2007

Ratings & Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.